2019 CYIR Finalized

58 UPDATE ON PULMONARY VASCULAR DISEASES Vinicio De Jesus Perez, MD, ATSF, FAHA, FCCP Stanford University Pulmonary and Critical Care Medicine Palo Alto, CA UPDATE ON PULMONARY VASCULAR DISEASES WEDNESDAY, MAY 22 CLINICAL CLASSIFICATION OF PULMONARY HYPERTENSION Simonneau G, Montani D, Celermajer DS, Denton CP, Gatzoulis M, Krowka M, Williams PG, Souza R. Haemodynamic definitions and updated clinical classifi- cation of pulmonary hypertension. European Respiratory Journal 2018. Summary Since the 1st World Symposium on Pulmonary Hypertension (WSPH), pulmonary hypertension (PH) has been defined as mean pulmonary arterial pressure (mPAP) ⩾ 25 mmHg at rest. Recent data from normal subjects has shown that nor- mal mPAP is 14.0±3.3 mmHg, and two standard deviations above this mean value would suggest mPAP ⩾ 20 mmHg as above the upper limit of normal. At the 6th WSPH, the definition of PH was changed to acknowledge that mPAP ⩾ 20mmHg should serve as the new cut-off. Since mPAP can be affected by cardiac output and fluid balance, it was proposed that pulmonary arterial hypertension (PAH) should be further defined as mPAP ⩾ 20mmHg, a pulmo- nary artery wedge pressure of ⩽ 15mmHg and a pulmonary vascular resistance of ⩾ 3 Woods Units. Regarding clinical classification, the main changes were the inclusion in group 1 of a subgroup “pulmonary arterial hypertension (PAH) long-term responders to calcium channel blockers”, due to the specific prognostic and management of these patients, and a subgroup “PAH with overt features of venous/ capillaries (pulmonary veno-occlusive disease/pulmonary capillary hemangiomatosis) involvement”, due to evidence suggesting a continuum between arterial, capillary and vein involvement in PAH. Finally, review of the data on use of exercise hemodynamics revealed too many uncertainties to allow the reintroduction of a definition of exercise PH. Comments 1. The new definition of PH is mPAP ⩾ 20 mmHg. 2. The new definition of PAH is mPAP ⩾ 20 mmHg, PAWP ⩽ 15mmHg and PVR ⩾ 3WU. 3. A clinically meaningful definition of exercise PH remains to be determined. 4. Thyroid disorders are no longer included in the clinical classifi- cation of PH. RISK STRATIFICATION AND TREATMENT OF PULMONARY ARTERIAL HYPERTENSION Galiè N, Channick RN, Frantz RP, Grünig E, Jing ZC, Moiseeva O, Preston IR, Pulido T, Safdar Z, Tamura Y, McLaughlin VV. Risk stratification and medical therapy of pulmonary arterial hypertension. Eur Respir J. 2019 Jan 24;53(1). Summary For most patients with PAH, early combination therapy has become the standard of care, but the decisions on adjusting existing or adding new medications has become a subject of intense research. The current treatment strat- egy is based on the severity of the newly diagnosed PAH patient as assessed by a multiparametric risk stratification approach. Different risk stratification tools (REVEAL, French Registry, COMPERA, SPAHR) have become available that integrate clinical, exercise, right ventricular function and hemodynamic parameters to define a low-, intermediate- or high-risk status according to the expected 1-year mortality. This stratification drives the new treatment algorithm for PAH which recommends initial oral combination therapy with an endothelin receptor antagonists and a phosphodi- esterase-5 inhibitor for low- or intermediate-risk patients. Patients at high risk should be started on upfront combina- tion therapy and an IV prostacyclin. Patients who achieve low risk status within 3-6 months should be maintained on therapy and followed closely; for patients who remain at intermediate risk, escalation to prostacyclin (i.e. triple therapy) is recommended. Finally, for those patients who fail to improve their risk status on triple therapy, early refer- ral to lung transplantation should be contemplated. Comments 1. Patients should be risk stratified at initial and follow up appoint- ments using a risk assessment tool. 2. Patients at low- and intermediate- riskshould be started on upfront combination therapy. 3. Initial monotherapy should be considered for patients with very mild disease or who are stable on one agent. 4. Patients with a positive acute vasoreactivity test should be treated with high doses of calcium channel blockers. 5. High risk patients should be treated with triple therapy that includes an IV prostacyclin.

RkJQdWJsaXNoZXIy MTM1ODMw